AR and prostate carcinoma: Lastly, research has shown that lysine-specific demethylase 1 (LSD1), an AR coactivator in prostate cancer, drives disease progression through SE-mediated oncogenic programs, which could be countered using LSD1 inhibitors to suppress CRPC growth 100.